Does Rallies show Form 4 insider transactions for GERN?

Yes. Rallies tracks GERN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is GERN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GERN. It does not provide personalized investment advice.

GERN (Geron Corp) Stock Analysis - Insider Trades

Geron Corp (GERN) is a publicly traded Healthcare sector company. As of May 20, 2026, GERN trades at $1.25 with a market cap of $789.07M and a P/E ratio of -11.41. GERN moved +3.28% today. Year to date, GERN is -7.58%; over the trailing twelve months it is -12.23%. Its 52-week range spans $1.04 to $4.65. Analyst consensus is buy with an average price target of $3.25. Rallies surfaces GERN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading GERN stock inside the company?

Recent GERN insider activity includes ROBERTSON MICHELLE sold 9.86K, LAWLIS V BRYAN bought 13.30K, Samuels Scott Alan bought 15.00K, SCARLETT JOHN A bought 12.50K, and Ziegler James bought 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

GERN Key Metrics

Key financial metrics for GERN
Metric	Value
Price	$1.25
Market Cap	$789.07M
P/E Ratio	-11.41
EPS	$-0.11
Dividend Yield	0.00%
52-Week High	$4.65
52-Week Low	$1.04
Volume	7.50M
Avg Volume	0
Revenue (TTM)	$196.12M
Net Income	$-67.31M
Gross Margin	0.00%

Recent GERN Insider Trades

ROBERTSON MICHELLE sold 9.86K (~$19.12K) on Feb 18, 2026.
LAWLIS V BRYAN bought 13.30K (~$15.67K) on May 9, 2025.
Samuels Scott Alan bought 15.00K (~$24.15K) on Feb 27, 2025.
SCARLETT JOHN A bought 12.50K (~$22.06K) on Feb 27, 2025.
Ziegler James bought 100.00K (~$160.00K) on Feb 27, 2025.

Latest GERN News

Geron to Present First Real-World RYTELO Data at EHA 2026 Congress — May 20, 2026
Geron Q1 Revenue Rises 8% to $51.8M, Net Loss Narrows to $3.6M — May 6, 2026
Geron Grants 2.5M Share Options at $1.73 Exercise Price with Four-Year Vesting — Apr 14, 2026
Geron Appoints Former Vanda GC Timothy Williams as Chief Legal Officer — Apr 13, 2026
Reblozyl Tops $2.3B Sales, Heightening Pressure on Geron’s Rytelo Growth — Mar 5, 2026

GERN Analyst Consensus

5 analysts cover GERN: 0 strong buy, 3 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.25.

Common questions about GERN

Who is trading GERN stock inside the company?: Recent GERN insider activity includes ROBERTSON MICHELLE sold 9.86K, LAWLIS V BRYAN bought 13.30K, Samuels Scott Alan bought 15.00K, SCARLETT JOHN A bought 12.50K, and Ziegler James bought 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for GERN?: Yes. Rallies tracks GERN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is GERN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GERN. It does not provide personalized investment advice.